First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
Key Highlights
- ➤Oct. 12 top-line data readout scheduled for ANB033 Cohort 1 celiac trial
- ➤ANB033 Cohort 1 evaluates prevention of gluten-challenge-induced mucosal damage
- ➤First Tracks will host investor webcast at 8:30am ET on Oct. 12
- ➤Pipeline includes rosnilimab for rheumatoid arthritis and ANB101 BDCA2 modulator
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.
A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event.
Get started
Create a free account to read the full story.